SCHEMBL4059226

SCHEMBL4059226

FC(F)(F)c1ccc(CCc2nc3ncc(-c4ccccc4)cc3[nH]2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.53
NOS1 P29475 1/20 0.53
NOS2 P35228 1/20 0.53
TRPV1 Q8NER1 2/20 0.50
PDE10A Q9Y233 2/20 0.44
NTRK1 P04629 1/20 0.41
NTRK2 Q16620 1/20 0.41
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
DGAT1 O75907 1/20 0.40
KCNH2 Q12809 1/20 0.40
SCN2A Q99250 2/20 0.40
NPBWR1 P48145 1/20 0.39
KIF11 P52732 1/20 0.39
PRMT5 O14744 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPK10 P53779 1/20 0.37
QPCT Q16769 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4058698 0.88 NOS3 (0.62) NOS3NOS1NOS2PDE10ARAB9A
SCHEMBL4057994 0.87 NOS3 (0.56) NOS3NOS1NOS2PDE10ARAB9A
SCHEMBL4055334 0.84 NOS3 (0.59) NOS3NOS1NOS2PDE10ANTRK1
SCHEMBL4053930 0.84 NOS3 (0.56) NOS3NOS1NOS2PDE10ARAB9A
SCHEMBL4057459 0.84 NOS3 (0.56) NOS3NOS1NOS2PDE10ANTRK1
SCHEMBL4056451 0.84 TRPV1 (0.44) NOS3NOS1NOS2TRPV1PDE10A
SCHEMBL4053513 0.82 NOS3 (0.51) NOS3NOS1NOS2TRPV1PDE10A
SCHEMBL4057686 0.81 NOS3 (0.56) NOS3NOS1NOS2PDE10ARAB9A
SCHEMBL4050811 0.81 NOS3 (0.53) NOS3NOS1NOS2PDE10ARAB9A
SCHEMBL13608669 0.81 TRPV1 (0.48) TRPV1PDE10ANTRK1NTRK2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NOS3 907/4885NOS1 879/4885NOS2 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.